Alexei V Tulin

List of Publications by Citations

33 papers	1,624 citations	20 h-index	34 g-index
34 ext. papers	1,818 ext. citations	9.3 avg, IF	4.8 L-index

#	Paper	IF	Citations
33	Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci. *Science*, **2003**, 299, 560-2	33.3	391
32	The Drosophila heterochromatic gene encoding poly(ADP-ribose) polymerase (PARP) is required to modulate chromatin structure during development. *Genes and Development*, **2002**, 16, 2108-19	12.6	163
31	Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. *Genes and Development*, **2009**, 23, 804-9	12.6	151
30	The roles of PARP1 in gene control and cell differentiation. *Current Opinion in Genetics and Development*, **2010**, 20, 512-8	4.9	111
29	Nucleosomal core histones mediate dynamic regulation of poly(ADP-ribose) polymerase 1 protein binding to chromatin and induction of its enzymatic activity. *Journal of Biological Chemistry*, **2007**, 282, 32511-9	5.4	86
28	Poly(ADP-ribosyl)ation of heterogeneous nuclear ribonucleoproteins modulates splicing. *Nucleic Acids Research*, **2009**, 37, 3501-13	20.1	73
27	Poly(ADP-Ribose) polymerase 1 (PARP-1) regulates ribosomal biogenesis in Drosophila nucleoli. *PLoS Genetics*, **2012**, 8, e1002442	6	68
26	Poly-ADP-ribose polymerase: machinery for nuclear processes. *Molecular Aspects of Medicine*, **2013**, 34, 1124-37	16.7	57
25	Poly (ADP-ribose) polymerase 1 is required for protein localization to Cajal body. *PLoS Genetics*, **2009**, 5, e1000387	6	56
24	Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases. *Current Topics in Developmental Biology*, **2003**, 56, 55-83	5.3	50
23	Drosophila histone H2A variant (H2Av) controls poly(ADP-ribose) polymerase 1 (PARP1) activation in chromatin. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 6205-10	11.5	49
22	Drosophila poly(ADP-ribose) glycohydrolase mediates chromatin structure and SIR2-dependent silencing. *Genetics*, **2006**, 172, 363-71	4	45
21	Bookmarking promoters in mitotic chromatin: poly(ADP-ribose)polymerase-1 as an epigenetic mark. *Nucleic Acids Research*, **2014**, 42, 7028-38	20.1	44
20	Uncoupling of the transactivation and transrepression functions of PARP1 protein. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6406-11	11.5	42
19	Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins. *International Journal of Molecular Sciences*, **2013**, 14, 16168-83	6.3	41
18	Poly(ADP-ribose) controls DE-cadherin-dependent stem cell maintenance and oocyte localization. *Nature Communications*, **2012**, 3, 760	17.4	34
17	Hit and run versus long-term activation of PARP-1 by its different domains fine-tunes nuclear processes. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 9941-9946	11.5	33

List of Publications

16	Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo. *EBioMedicine*, **2016**, 13, 90-98	8.8	27
15	Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-ribosyl)ation. *Molecular Cell*, **2014**, 53, 831-42	17.6	26
14	Minor grove binding ligands disrupt PARP-1 activation pathways. *Oncotarget*, **2014**, 5, 428-37	3.3	20
13	Re-evaluating PARP1 inhibitor in cancer. *Nature Biotechnology*, **2011**, 29, 1078-9	44.5	15
12	Small-molecule collection and high-throughput colorimetric assay to identify PARP1 inhibitors. *Methods in Molecular Biology*, **2011**, 780, 491-516	1.4	10
11	Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. *Biochemical Pharmacology*, **2019**, 167, 149-162	6	9
10	Poly(ADP-Ribosyl)ation of hnRNP A1 Protein Controls Translational Repression in Drosophila. *Molecular and Cellular Biology*, **2016**, 36, 2476-86	4.8	7
9	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. *Leukemia and Lymphoma*, **2019**, 60, 1098-1101	1.9	7
8	Structurally unique PARP-1 inhibitors for the treatment of prostate cancer. *Pharmacology Research and Perspectives*, **2020**, 8, e00586	3.1	2
7	Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy. *Cancers*, **2021**, 13,	6.6	2
6	High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection. *Methods in Molecular Biology*, **2017**, 1608, 299-312	1.4	2
5	Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. *Medicinal Chemistry Research*, **2020**, 29, 962-978	2.2	1
4	Poly(ADP-ribose) polymerase 1 in genome-wide expression control in Drosophila. *Scientific Reports*, **2020**, 10, 21151	4.9	1
3	Poly(ADP-ribosyl)ating pathway regulates development from stem cell niche to longevity control.. *Life Science Alliance*, **2022**, 5,	5.8	1
2	PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.. *BMC Cancer*, **2022**, 22, 557	4.8	0
1	PARP-1 Interaction with and Activation by Histones and Nucleosomes. *Methods in Molecular Biology* , **2017**, 1608, 255-267	1.4	